A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Exclusion Criteria

• •Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or UC, or has clinical findings suggestive of UC
• •Has CD that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
• •Has had extensive bowel resection (\>100 cm), and/or more than 3 resections, and/or has a known diagnosis of short bowel syndrome
• •Is currently receiving total parenteral nutrition, tube feeding, or a formula diet
• •Has positive findings on a subjective neurological screening questionnaire
• •Has a concurrent, clinically significant, serious, unstable comorbidity
• •Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors
• •Is currently participating in any other interventional study or has received any investigational therapy within 30 days
• •Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
• •Unable to attend study visits or comply with study procedures
• •Has a history of any major neurological disorders, including: stroke, multiple sclerosis, brain tumor, demyelinating, or neurodegenerative disease